Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1

April 9, 2019
Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …

News

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019
Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …

News
simon-sturge-kymab-tile

Kymab announces Merck exec Simon Sturge as new CEO

April 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …

Appointment
real_world

Protecting public health: Is real-world evidence the key?

April 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …

Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

News
shutterstock_159488225

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019
Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …

News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019
Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …

News
johnson_and_johnson_jj

€100m expansion of J&J’s Limerick manufacturing facility to bring up to 300 jobs

April 8, 2019
Manufacturing and Production, Sales and Marketing

Johnson & Johnson has revealed plans to expand its existing Vision Care facilities at the National Technology Park in Limerick, …

News
shutterstock_243110086

Merrimack shuts down development of investigational cancer drug, staff cuts to follow

April 8, 2019
Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma

Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 5, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma

As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …

News

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019
Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …

News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …

News
920x920

Sacklers file motion to throw lawsuit out of court

April 5, 2019
Medical Communications Massachusetts, OxyContin, Purdue Pharma, opioid crisis, opioids, sackler

Members of the Sackler family have asked a judge to throw a lawsuit – filed by Massachusetts attorney general Maura …

News

Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies

April 5, 2019
Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research

Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …

News
theo_harold

Crescendo Biologics selects current CFO Theodora Harold as new CEO

April 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack …

Appointment
astrazeneca-sign

AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome

April 4, 2019
Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma

AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …

News
nhs_andrew_tatlow

NHS England threatened legal action against Oxford University hospitals trust

April 4, 2019
Medical Communications, Research and Development Hopsitals, NHS, NHS England, OUH, cancer screening, patients

NHS England threatened to sue Oxford University hospitals (OUH) NHS trust after they objected to the former’s controversial decision to …

News
dr_patrick_soon-shiong_14212355607

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

April 4, 2019
Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …

News

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

News

HPV vaccine prevents 90% of cervical pre-cancer cases in Scotland, research shows

April 4, 2019
Research and Development HPV, Scotland, cervical cancer, immunity, vaccines, virus

Routine vaccination of girls in Scotland against HPV has led to a dramatic drop in cases of cervical cancer, according …

News
The Gateway to Local Adoption Series

Latest content

Five Facts about spinal muscular atrophy

January 28, 2026

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026

Everdrone appoints David Borkmann as Senior Medical Advisor

January 28, 2026

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026